The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.
 
Helena Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Bristol-Myers Squibb/Roche; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Orion Clinical; Taiho Oncology; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Jyoti Patel
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Guardant Health; Sanofi; Takeda Science Foundation
Travel, Accommodations, Expenses - Tempus
 
Nisha Mohindra
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Roche; Catalyst Pharmaceuticals; Genentech
Research Funding - AstraZeneca/MedImmune (Inst); Pfizer (Inst)
 
Susan Scott
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; EMD Serono; Johnson & Johnson/Janssen; Merus; Summit Therapeutics
Research Funding - Black Diamond Therapeutics (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst)
 
Julia Rotow
Honoraria - AstraZeneca; Daiichi Sankyo; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blossom Hill; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daiichi Sankyo; EMD Serono; Gilead Sciences; Johnson & Johnson/Janssen; Merus; Novocure; Nuvalent, Inc.; Nuvation Bio; Pfizer; Sanofi/Regeneron; Summit Therapeutics; Takeda
Research Funding - Abbvie (Inst); Altor BioScience (Inst); AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Blossom Hill (Inst); Blueprint Medicines (Inst); Bristol-Myer Squibb; Daiichi Sankyo (Inst); DualityBio (Inst); Enliven Therapeutics (Inst); EpimAb (Inst); ImmunityBio (Inst); Loxo (Inst); ORIC Pharmaceuticals (Inst); RedCloud Biotech (Inst); Regeneron (Inst); Summit Therapeutics (Inst); Synthekine (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Black Diamond Therapeutics; BMS; Daiichi Sankyo; Johnson & Johnson/Janssen; Merus
 
Christina Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Lilly; Natera; Nuvalent, Inc.; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blossom Hills (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Summit Therapeutics (Inst); Systimmune (Inst); TP Therapeutics (Inst)
 
Danny Nguyen
Honoraria - Black Diamond Therapeutics; Janssen Oncology; Taiho Pharmaceutical
Consulting or Advisory Role - Black Diamond Therapeutics; Janssen Oncology
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen; Taiho Oncology
Other Relationship - Novartis; Pfizer; Seagen; Takeda
(OPTIONAL) Uncompensated Relationships - Johnson & Johnson/Janssen; Novartis; Takeda
 
Alex Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Sarah Gordon
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Nuvation Bio
 
Haobin Chen
No Relationships to Disclose
 
James Stevenson
Honoraria - MJH Life Sciences
Consulting or Advisory Role - OptumHealth
Research Funding - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Henlius (Inst); Merck Sharp & Dohme (Inst); PrECOG (Inst)
 
Manmeet Ahluwalia
Stock and Other Ownership Interests - doctible; Live AI; MedInnovate Advisors LLC; MimiVax; Modifi Bio; TriSalus Life Sciences
Consulting or Advisory Role - AlloVir; Apollomics; Autem Therapeutics; Bayer; Bugworks; Equillium; GT Medical Technologies; Incyte; Menarini Group; Modifi Bio; Pyramid Biosciences; Recordati; SERVIER; Sumitomo Dainippon Pharma Oncology; VBI Vaccines; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
Other Relationship - Idorsia (I); ResMed (I)
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - SCRI at Mary Crowley Cancer Research
 
Shetal Patel
Consulting or Advisory Role - Astellas Pharma; Genentech; IQvia; Pharmacosmos
Research Funding - Amgen (Inst); ASCO (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Bristol-Myers Squibb (Inst); Dracen (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MediLink Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst)
Travel, Accommodations, Expenses - DAVA Oncology; Genentech/Roche
 
David Berz
Employment - Valkyrie Clinical Trials
Leadership - Jazz Pharmaceuticals; Sun Pharma
Honoraria - EMD Serono; Sun Pharma
Research Funding - Ascendis Pharma; BeiGene; BioNTech; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb; eFFECTOR Therapeutics; Faeth Therapeutics; G1 Therapeutics; Genprex; Hongyun Biotech; Incyte; InhibRx; Mirati Therapeutics; Seagen; Summit Therapeutics; WhiteOak; Xencor
Travel, Accommodations, Expenses - EMD Serono; Jazz Pharmaceuticals
 
Chao Huang
Stock and Other Ownership Interests - Vanguard Funds
Honoraria - Ipsen
Consulting or Advisory Role - Biodesix; Ipsen
Speakers' Bureau - Curio Science; Targeted Oncology
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); EpicentRx; Genentech/Roche (Inst); Henlius (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Regenxbio (Inst); Summit Therapeutics (Inst)
 
Sergey Yurasov
Employment - Black Diamond Therapeutics; Immune Design; Nuvation Bio
Leadership - Black Diamond Therapeutics; Immune Design
Stock and Other Ownership Interests - Black Diamond Therapeutics; Nuvation Bio
Travel, Accommodations, Expenses - Black Diamond Therapeutics
 
Julio Hajdenberg
Employment - Black Diamond Therapeutics
Stock and Other Ownership Interests - Black Diamond Therapeutics
Travel, Accommodations, Expenses - Black Diamond Therapeutics
 
Shannon Matheny
Employment - Black Diamond Therapeutics
Stock and Other Ownership Interests - Black Diamond Therapeutics
Travel, Accommodations, Expenses - Black Diamond Therapeutics
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeOne Medicines (Inst); Biohaven Pharmaceuticals (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Ottimo Pharma (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Summit Therapeutics (Inst); Zai Lab (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); BlossomHill Therapeutics (Inst); Boehringer Ingelheim (Inst); Boundless Bio (Inst); Bristol-Myers Squibb (Inst); Carisma Therapeutics (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Modex Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Puma Biotechnology (Inst); RasCal (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Shanghai Junshi BioSciences (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Systimmune (Inst); Taiho Oncology (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi